Cerebrospinal fluid biomarkers for Alzheimer's disease in Down syndrome

Alain D. Dekker, Juan Fortea, Rafael Blesa, Peter P. De Deyn

Producció científica: Contribució a una revistaArticleRecercaAvaluat per experts

28 Cites (Scopus)

Resum

© 2017 The Authors Down syndrome (DS), present in nearly six million people, is associated with an extremely high risk to develop Alzheimer's disease (AD). Amyloid-β and tau pathology are omnipresent from age 40 years onward, but clinical symptoms do not appear in all DS individuals. Dementia diagnostics is complex in this population, illustrating the great need for predictive biomarkers. Although blood biomarkers have not yet proven useful, cerebrospinal fluid (CSF) biomarkers (low amyloid-β42, high t-tau, and high p-tau) effectively contribute to AD diagnoses in the general population and are increasingly used in clinical practice. Surprisingly, CSF biomarkers have been barely evaluated in DS. Breaking the taboo on CSF analyses would finally allow for the elucidation of its utility in (differential) diagnoses and staging of disease severity. A sensitive and specific biomarker profile for AD in DS would be of paramount importance to daily care, adaptive caregiving, and specific therapeutic interventions.
Idioma originalEnglish
Pàgines (de-a)1-10
RevistaAlzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring
Volum8
DOIs
Estat de la publicacióPublicada - 1 de gen. 2017

Fingerprint

Navegar pels temes de recerca de 'Cerebrospinal fluid biomarkers for Alzheimer's disease in Down syndrome'. Junts formen un fingerprint únic.

Com citar-ho